| Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 | Dec'13 | Dec'12 | Dec'11 | Dec'10 | Dec'09 |
|---|---|---|---|---|---|---|---|---|---|---|
Operating activities: | ||||||||||
Net loss | ||||||||||
-158,650 | -222,693 | -125,530 | -140,111 | -120,486 | -76,141 | -62,520 | -53,782 | -152,030 | -66,265 | -81,683 |
Adjustments to reconcile net loss to net cash used by operating activities | ||||||||||
Share-based compensation | ||||||||||
127,300 | 78,900 | 63,800 | 52,471 | 41,836 | 40,619 | 31,406 | 25,340 | 19,984 | 14,330 | 11,849 |
Depreciation and amortization | ||||||||||
23,774 | 26,032 | 24,269 | 18,034 | 14,505 | 12,490 | 8,615 | 6,159 | 4,170 | 3,562 | 3,260 |
Amortization of premiums, accretion of discounts, and (gains) losses on debt securities | ||||||||||
4,916 | 2,530 | -497 | -4,746 | -2,846 | 150 | -1,883 | -2,574 | -12,474 | -3,429 | -3,622 |
Amortization of right-of-use assets | ||||||||||
9,740 | - | - | - | - | - | - | - | - | - | - |
(Gains) losses on equity securities | ||||||||||
50,124 | 7,336 | 33,777 | 0 | - | - | - | - | - | - | - |
Amortization of right-of-use-assets | ||||||||||
9,740 | - | - | - | - | - | - | - | - | - | - |
Loss on disposals of property and equipment | ||||||||||
-1,853 | 0 | 0 | - | - | - | - | - | - | - | - |
Gain on Immunomedics warrant derivative | ||||||||||
- | - | - | - | 0 | - | - | - | - | - | - |
Income tax benefit on unrealized loss on available-for-sale securities | ||||||||||
0 | 0 | 33,357 | 0 | - | - | - | - | - | - | - |
Deferred income taxes | ||||||||||
0 | -23,653 | 0 | 0 | 0 | - | - | - | - | - | - |
Other long-term liabilities | ||||||||||
- | - | - | -882 | - | - | - | - | - | - | - |
Deferred rent and other long-term liabilities | ||||||||||
- | - | - | - | -921 | -734 | -606 | 716 | 2,247 | 198 | 1,248 |
Changes in operating assets and liabilities | ||||||||||
Interest receivable | ||||||||||
- | - | - | - | - | - | - | - | -141 | -568 | -538 |
Accounts receivable, net | ||||||||||
89,720 | 45,233 | 22,846 | 8,998 | 13,682 | 9,740 | -3,935 | -21,512 | 35,676 | -60,843 | 71,936 |
Inventories | ||||||||||
32,693 | -6,739 | -8,146 | 11,161 | 13,512 | 16,378 | -10,674 | 28,278 | 9,469 | 0 | 0 |
Prepaid expenses and other assets | ||||||||||
-2,459 | 14,567 | 2,170 | 4,378 | 1,952 | 5,232 | 1,817 | 1,551 | 1,574 | -4,056 | 839 |
Lease liability | ||||||||||
6,660 | - | - | - | - | - | - | - | - | - | - |
Accounts payable and accrued liabilities | ||||||||||
- | - | - | 29,939 | 6,539 | 18,448 | 1,493 | 3,082 | 27,265 | 6,287 | 3,617 |
Deferred revenue | ||||||||||
-33,600 | -33,913 | -16,878 | -36,631 | -48,376 | -23,181 | 5,827 | 35,109 | 8,437 | -20,200 | 68,569 |
Other liabilities | ||||||||||
47,451 | 34,757 | 18,944 | - | - | - | - | - | - | - | - |
Net cash used by operating activities | ||||||||||
-163,737 | -203,536 | -118,900 | -96,971 | -133,203 | -59,999 | -1,110 | 10,881 | -124,031 | 6,808 | -61,755 |
Investing activities: | ||||||||||
Purchases of securities | ||||||||||
992,976 | 512,334 | 513,016 | 603,772 | 754,663 | 451,274 | 483,182 | 505,066 | 479,389 | 453,599 | 396,840 |
Proceeds from maturities of securities | ||||||||||
786,000 | 398,722 | 653,200 | 699,800 | 367,200 | 504,100 | 480,700 | 425,151 | 498,959 | 443,256 | 251,919 |
Proceeds from sales of securities | ||||||||||
0 | 140,352 | 60,056 | 0 | 30,005 | 972 | 0 | 10,824 | 0 | 2,321 | 2,092 |
Purchases of property and equipment | ||||||||||
70,753 | 21,219 | 28,722 | 27,835 | 13,392 | 17,176 | 22,154 | 10,485 | 11,252 | 3,548 | 4,589 |
Acquisition of manufacturing facility | ||||||||||
0 | 0 | 41,657 | 0 | 0 | - | - | - | - | - | - |
Acquisition of Cascadian Therapeutics, Inc., net of cash acquired | ||||||||||
0 | 598,151 | 0 | 0 | - | - | - | - | - | - | - |
Investments in other non-current assets | ||||||||||
- | - | - | - | - | - | - | - | 5,764 | -26 | 28 |
Purchase of cost-method investment | ||||||||||
- | - | - | - | 5,000 | 0 | 0 | - | - | - | - |
Net cash provided by investing activities | ||||||||||
-277,729 | -592,630 | 129,861 | 68,193 | -375,850 | 36,622 | -24,636 | -79,576 | 2,554 | -11,544 | -147,446 |
Financing activities: | ||||||||||
Net proceeds from issuance of common stock | ||||||||||
548,691 | 658,242 | 0 | 0 | 526,618 | 0 | 0 | - | 168,053 | 0 | 192,141 |
Proceeds from exercise of stock options and employee stock purchase plan | ||||||||||
89,151 | 55,165 | 41,311 | 35,196 | 27,763 | 16,188 | 35,199 | 35,724 | 19,931 | 7,377 | 4,746 |
Net cash provided by financing activities | ||||||||||
637,842 | 713,407 | 41,311 | 35,196 | 554,381 | 16,188 | 35,199 | 35,724 | 187,984 | 7,377 | 196,887 |
Net increase (decrease) in cash and cash equivalents | ||||||||||
196,376 | -82,759 | 52,272 | 6,418 | 45,328 | -7,189 | 9,453 | -32,971 | 66,507 | 2,641 | -12,314 |